With over 20 CGTs projected to be approved by 2025, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth, unstable infrastructure, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization.

To realize this potential, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further, transforming our healthcare system to guarantee scalable and sustainable growth.

Don’t get left behind.

Join us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers, 5 case-studies and over 1500+ fellow CGT attendees – we will pioneer a new gold standard for commercialization, readying the world for CGT as a frontline treatment.